In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.
|Articles|March 18, 1998
IDSI pursues NASDAQ listing
Breast imaging developer Imaging Diagnostic Systems of Plantation, FL, is trying to get listed on the NASDAQ stock exchange, but it has run into difficulty due to the stock exchange's listing requirements. One of NASDAQ's requirements is that IDSI
Advertisement
Breast imaging developer Imaging Diagnostic Systems of Plantation, FL, is trying to get listed on the NASDAQ stock exchange, but it has run into difficulty due to the stock exchange's listing requirements. One of NASDAQ's requirements is that IDSI execute a reverse stock split to bring the company's share prices above $4; however, IDSI's board determined that a reverse split would be detrimental to shareholders. IDSI reported that it would appeal the NASDAQ's requirements and continue to seek the listing.
In other IDSI news, the company announced that it has signed an agreement with Imation that enables IDSI to sell Imation's DryView laser printers with its CT Laser Mammography system, when CTLM becomes commercially available. IDSI will also begin to market DryView in the U.S. directly and internationally through its distributors. IDSI added a distributor in Turkey with the signing of an agreement with Emtron, which will have rights to market CTLM in the country for 18 months.
Advertisement
Related to this article
Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?
Catch up on a variety of FDA news in radiology from the past week.
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Software That Combines MRI Enhancement of PET Imaging with Automated Quantification of Amyloid and Tau PET
2
Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
3
Is Private Practice Radiology as Important as an Amusement Park?
4
Diagnostic Imaging’s Weekly Scan: September 13 — September 19
5